{"id":455325,"date":"2021-03-10T17:03:21","date_gmt":"2021-03-10T22:03:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=455325"},"modified":"2021-03-10T17:03:21","modified_gmt":"2021-03-10T22:03:21","slug":"achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/","title":{"rendered":"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>London, UK 10 March 2021<\/strong> \u2013 Achilles Therapeutics plc (\u201cAchilles\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an abstract was selected for poster presentation at the\u00a0American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held in a virtual format from April 10-15, 2021.<\/p>\n<p align=\"justify\">Details of the abstract and poster presentation are as follows:<\/p>\n<p>\n        <strong>Abstract Title:\u00a0<\/strong>Characterization of a novel clonal neoantigen reactive T cell (cNeT) product through a comprehensive translational research program<strong><br \/><strong>Poster Number:<\/strong><\/strong>\u00a01508<strong><br \/><strong>Poster Session Category \/ Title:\u00a0<\/strong><\/strong>Immunology \/ Adoptive Cell Therapy<strong><br \/><\/strong><br \/> The abstract and full session details can be found at\u00a0www.aacr.org. The AACR poster website will be launched on\u00a0Saturday, April 10<strong>,<\/strong>\u00a02021.<\/p>\n<p>\n        <strong>About Achilles Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I\/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS\u2122 bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.<\/p>\n<p>\n        <strong>Further information:<\/strong>\n      <\/p>\n<p>\n        <strong>Lee M. Stern \u2013 VP, IR &amp; External Communications<\/strong><br \/>\n        <br \/>+1 (332) 373-2634<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QVjQNXiL7p50ph26aDQiRB35HQQ2558hDEHx9zo3LWE_QNvZES0-puIGWVMzfCr_jHzAIpU__kcR2PfaBY5z4NYaPFk6aKJNDD_KH7Mymgc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>l.stern@achillestx.com<\/u><\/a><\/p>\n<p>\n        <strong>Consilium Strategic Communications<\/strong><br \/>\n        <br \/> Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner<br \/> +44 (0) 203 709 5000<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EOv5PnsN39uZ2bZ0OzlaDd_uCFvWTFWBo823j-AR6UWnkXw9Oo6IrsrZDzrQt2WISmetgi3p7VbH6I7I3kN8PNmPSUCZQfSHaxoEuYcNqNFsU1f7RQW1RpgNcCVOrd3Y\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>achillestx@consilium-comms.com<\/u><\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MTYwOSM0MDA4ODI0OTEjNzAwMDExMzIz\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/05d43321-ce08-4aa2-8dbc-9a63c1f15f3e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021 London, UK 10 March 2021 \u2013 Achilles Therapeutics plc (\u201cAchilles\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an abstract was selected for poster presentation at the\u00a0American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held in a virtual format from April 10-15, 2021. Details of the abstract and poster presentation are as follows: Abstract Title:\u00a0Characterization of a novel clonal neoantigen reactive T cell (cNeT) product through a comprehensive translational research programPoster Number:\u00a01508Poster Session Category \/ Title:\u00a0Immunology \/ Adoptive Cell Therapy The abstract and full session details can be found at\u00a0www.aacr.org. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-455325","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021 London, UK 10 March 2021 \u2013 Achilles Therapeutics plc (\u201cAchilles\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an abstract was selected for poster presentation at the\u00a0American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held in a virtual format from April 10-15, 2021. Details of the abstract and poster presentation are as follows: Abstract Title:\u00a0Characterization of a novel clonal neoantigen reactive T cell (cNeT) product through a comprehensive translational research programPoster Number:\u00a01508Poster Session Category \/ Title:\u00a0Immunology \/ Adoptive Cell Therapy The abstract and full session details can be found at\u00a0www.aacr.org. &hellip; Continue reading &quot;Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-10T22:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MTYwOSM0MDA4ODI0OTEjNzAwMDExMzIz\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021\",\"datePublished\":\"2021-03-10T22:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/\"},\"wordCount\":272,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MTYwOSM0MDA4ODI0OTEjNzAwMDExMzIz\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/\",\"name\":\"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MTYwOSM0MDA4ODI0OTEjNzAwMDExMzIz\",\"datePublished\":\"2021-03-10T22:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MTYwOSM0MDA4ODI0OTEjNzAwMDExMzIz\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MTYwOSM0MDA4ODI0OTEjNzAwMDExMzIz\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/","og_locale":"en_US","og_type":"article","og_title":"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021 - Market Newsdesk","og_description":"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021 London, UK 10 March 2021 \u2013 Achilles Therapeutics plc (\u201cAchilles\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an abstract was selected for poster presentation at the\u00a0American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held in a virtual format from April 10-15, 2021. Details of the abstract and poster presentation are as follows: Abstract Title:\u00a0Characterization of a novel clonal neoantigen reactive T cell (cNeT) product through a comprehensive translational research programPoster Number:\u00a01508Poster Session Category \/ Title:\u00a0Immunology \/ Adoptive Cell Therapy The abstract and full session details can be found at\u00a0www.aacr.org. &hellip; Continue reading \"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-10T22:03:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MTYwOSM0MDA4ODI0OTEjNzAwMDExMzIz","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021","datePublished":"2021-03-10T22:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/"},"wordCount":272,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MTYwOSM0MDA4ODI0OTEjNzAwMDExMzIz","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/","name":"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MTYwOSM0MDA4ODI0OTEjNzAwMDExMzIz","datePublished":"2021-03-10T22:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MTYwOSM0MDA4ODI0OTEjNzAwMDExMzIz","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MTYwOSM0MDA4ODI0OTEjNzAwMDExMzIz"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/455325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=455325"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/455325\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=455325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=455325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=455325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}